Free tool
FAERS Monitor: Eliquis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202155 or its brand name (Eliquis, Apixaban). Reports on generic versions are filed under their own applications.
Reports
280,966
Serious
210,870
75% of reports
Hospitalization
92,944
Death reported
40,921
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death25,095
- dyspnoea13,002
- fatigue12,518
- off label use12,368
- atrial fibrillation10,940
- diarrhoea10,264
- fall9,795
- cerebrovascular accident9,076
- dizziness9,007
- nausea8,776
- headache7,976
- thrombosis7,555
- asthenia6,556
- pneumonia6,443
- cardiac disorder6,260
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 7 |
| 2009 | 20 |
| 2010 | 36 |
| 2011 | 117 |
| 2012 | 26 |
| 2013 | 1,174 |
| 2014 | 3,800 |
| 2015 | 7,567 |
| 2016 | 12,344 |
| 2017 | 17,213 |
| 2018 | 21,671 |
| 2019 | 27,146 |
| 2020 | 30,826 |
| 2021 | 34,744 |
| 2022 | 29,838 |
| 2023 | 26,565 |
| 2024 | 26,750 |
| 2025 | 23,878 |
| 2026 | 17,241 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,773,193 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| atrial fibrillationSignal | 10,940 | 9.3 | 9.2 | 72,713 |
| thrombosisSignal | 7,555 | 7.7 | 7.5 | 39,743 |
| cardiac disorderSignal | 6,260 | 5.3 | 5.2 | 20,445 |
| cerebrovascular accidentSignal | 9,076 | 4.2 | 4.1 | 20,951 |
| fallSignal | 9,795 | 2.2 | 2.2 | 6,626 |
| deathSignal | 25,095 | 2.2 | 2.2 | 16,950 |
| dyspnoea | 13,002 | 1.7 | 1.7 | 4,075 |
| pneumonia | 6,443 | 1.5 | 1.5 | 1,067 |
| dizziness | 9,007 | 1.4 | 1.3 | 856 |
| asthenia | 6,556 | 1.3 | 1.3 | 483 |
| fatigue | 12,518 | 1.2 | 1.2 | 454 |
| diarrhoea | 10,264 | 1.2 | 1.2 | 326 |
| off label use | 12,368 | 1.1 | 1.0 | 41 |
| headache | 7,976 | 1.0 | 0.9 | 20 |
| nausea | 8,776 | 0.8 | 0.8 | 321 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.